USC Norris | Strategic Alliance Partners

Latest from USC Norris


Combinations Gain Momentum as First-Line Treatments for Unresectable Hepatocellular Carcinoma

May 25, 2022

A panel of hepatobiliary tumor experts discuss several pivotal phase 3 clinical trials examining combination approaches that have expanded or are anticipated to expand the treatment armamentarium for treatment-naïve patients with unresectable hepatocellular carcinoma.

Nivolumab Plus SOC Misses PFS End Point of CheckMate-9X8 Trial, But Provides Notable Benefit in Select mCRC Subsets

February 18, 2022

Heinz-Josef Lenz, MD, discusses the safety and efficacy of nivolumab plus standard of care in patients with metastatic colorectal cancer, shares additional insight from the CheckMate-9X8 trial, and alludes to next steps with further exploring the regimen in specific subsets who appear to derive benefit from this approach.

Nivolumab Plus mFOLFOX6 and Bevacizumab Misses PFS End Point in mCRC

January 23, 2022

The addition of nivolumab to mFOLFOX6 and bevacizumab failed to demonstrate a statistically significant improvement in progression-free survival vs mFOLFOX6 and bevacizumab alone in previously untreated patients with metastatic colorectal cancer, according to findings from the phase 2/3 CheckMate 9X8 trial.

Immunotherapy Approvals Overcome Years of Stagnation in GI Cancers

December 28, 2021

Syma Iqbal, MD, shares the main highlights from an IPC meeting, which centered on the evolving landscapes and importance of implementing best practices for patients with hepatobiliary cancers, locally advanced and advanced pancreatic cancer, advanced gastric/gastroesophageal junction cancer, and metastatic colorectal cancer.

Sequencing Strategies May Shift With Emerging Options in GI Malignancies

December 24, 2021

With the rapid uptake of novel therapies, including immunotherapy and targeted therapy, shifts in treatment strategies are anticipated in hepatobiliary cancers, locally advanced and advanced pancreatic cancer, gastric/gastroesophageal junction cancers, and metastatic colorectal cancer.

Nivolumab Plus Low-Dose Ipilimumab Provides Robust, Durable Clinical Benefit in Frontline MSI-H/dMMR mCRC

November 10, 2021

The combination of nivolumab and low-dose ipilimumab resulted in a deep and durable clinical benefit when used in the first-line treatment of patients with microsatellite instability–high and mismatch repair deficient metastatic colorectal cancer.

Dr. El-Khoueiry on Immunotherapy Combinations in HCC

July 26, 2019

Anthony B. El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, discusses immunotherapy combination in hepatocellular carcinoma (HCC).

Dr. El-Khoueiry on Choosing Between Immunotherapy Agents and TKIs in HCC

July 19, 2019

Anthony B. El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, discusses choosing between immunotherapy agents and TKIs in hepatocellular carcinoma (HCC).

Dr. Lenz on Next Steps With Immunotherapy in mCRC

June 19, 2019

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses next steps with immunotherapy in metastatic colorectal cancer.